GENMAB A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,954 DKK | +2.04% |
|
-2.57% | -9.30% |
| 04-16 | Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug | MT |
| 04-16 | Genmab A/S Announces DARZALEX Sales Results for the First Quarter of 2024 | CI |
| Sales 2024 * | 19.66B 2.82B 226B | Sales 2025 * | 23.51B 3.37B 270B | Capitalization | 127B 18.18B 1,455B |
|---|---|---|---|---|---|
| Net income 2024 * | 5.11B 732M 58.6B | Net income 2025 * | 6.76B 969M 77.55B | EV / Sales 2024 * | 5.1 x |
| Net cash position 2024 * | 26.57B 3.81B 305B | Net cash position 2025 * | 33.5B 4.8B 384B | EV / Sales 2025 * | 3.97 x |
| P/E ratio 2024 * |
25
x | P/E ratio 2025 * |
19.2
x | Employees | 2,204 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.87% |
More Fundamentals
* Assessed data
More news
Latest transcript on Genmab A/S
More recommendations
More press releases
More news
| 1 day | +2.04% | ||
| 1 week | -2.57% | ||
| Current month | -6.21% | ||
| 1 month | -6.21% | ||
| 3 months | +2.17% | ||
| 6 months | -2.62% | ||
| Current year | -9.30% |
1 week
1 915.50
2 054.00
1 month
1 915.502 132.00
Current year
1 825.002 227.00
1 year
1 825.002 939.00
3 years
1 825.003 327.00
5 years
1 075.503 327.00
10 years
180.103 327.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 31/12/98 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 31/12/06 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 22/03/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 31/12/16 |
| Director/Board Member | 73 | 31/10/03 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 63 | 31/12/15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.64% | 192 M€ | +13.43% | ||
| 1.28% | 49 M€ | +5.28% | ||
| 1.01% | 96 M€ | -1.45% | ||
| 0.75% | 18 M€ | +3.79% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 1,954 | +2.04% | 108,599 |
| 25/04/24 | 1,916 | -2.87% | 157,995 |
| 24/04/24 | 1,972 | -1.79% | 150,555 |
| 23/04/24 | 2,008 | -1.08% | 131,041 |
| 22/04/24 | 2,030 | +1.20% | 108,395 |
Delayed Quote Nasdaq Copenhagen, April 26, 2024 at 03:59 pm
More quotes
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Calendar
02/05/2024
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
1,954
DKK
Average target price
2,418
DKK
Spread / Average Target
+23.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.30% | 18.15B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B | |
| -24.71% | 8.24B |
- Stock Market
- Equities
- GMAB Stock
